Sunshine Biopharma wins US patent for coronavirus treatment technology

Sunshine Biopharma

Sunshine Biopharma

SBFM

0.00
  • Sunshine Biopharma secured U.S. Patent 12,624,066 B2 covering small-molecule coronavirus treatments designed to inhibit viral replication.
  • Patent targets the PLpro enzyme, a viral function the company views as less vulnerable to mutation-driven treatment resistance.
  • Program is ready for GLP studies, a prerequisite step before clinical trials.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sunshine Biopharma Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202605290800ACCESSWRNAPR_____1171632) on May 29, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.